Indivior Soars 16.09% on Q2 Earnings Boost $450M Volume Ranks 320th in Market Activity

On July 31, 2025, Indivior (INDV) surged 16.09% with a trading volume of $0.45 billion, marking a 191.38% increase from the previous day and ranking 320th in market activity. This momentum followed the company’s Q2 2025 earnings report, which highlighted a 9% year-over-year rise in SUBLOCADE net revenue to $209 million, driven by volume growth and pricing stability in the U.S. market for SUBOXONE Film. The firm also raised its full-year financial guidance, projecting higher total net revenue and adjusted EBITDA ranges, reflecting improved performance in the first half of 2025.

Indivior’s strategic initiatives, including the “Indivior Action Agenda,” aim to bolster U.S. SUBLOCADE growth and streamline operations. Recent leadership additions, such as Chief Commercial Officer Patrick Barry and Independent Director Tony Kingsley, underscore efforts to strengthen governance and commercial capabilities. The company also completed its delisting from the London Stock Exchange, now trading exclusively on Nasdaq, aligning with its U.S.-focused growth strategy. Additionally, Indivior’s inclusion in the Russell 2000 and Russell 3000 indices broadened its market visibility, while new clinical data on SUBLOCADE’s efficacy for high-fentanyl-use patients reinforced its therapeutic value.

A backtesting analysis of a strategy purchasing the top 500 stocks by daily trading volume and holding them for one day showed a 166.71% return from 2022 to the present, significantly outperforming the benchmark’s 29.18% return. This strategy’s success, attributed to capturing high-liquidity stocks and managing risk, highlights the potential of volume-driven momentum in short-term trading, particularly during periods of market volatility and shifting liquidity dynamics.